About Saul Priceman
- Supplementing a patient’s immune response by engineering their killer white blood cells (CAR T-cells) to recognize, bind to, and eliminate the tumor is a new and transformational area of cancer immunotherapy in other forms of chemotherapy-resistant cancers.
- Dr. Saul Priceman will use laboratory models of prostate cancer to evaluate how engineered CAR T-cells bind to prostate cancer cells and cause their death.
- Further, combining CAR T-cells that bind with PSA (prostate specific antigen) and PSCA (prostate stem cell antigen) may improve efficacy of immunotherapies in treating patients with advanced metastatic prostate cancer.
- If successful, Dr. Priceman’s research will lead to an innovative clinical trial testing engineered patient CAR T-cells as a new treatment for advanced, treatment-resistant prostate cancer.
What this means for patients: Development of a highly specific T-cell therapy for prostate cancer is a critical objective for advanced prostate cancer treatment. The path to the clinic for this project has all its milestones defined. This science will support and inform the appropriate clinical translation of this first-in-field treatment.
2015 Lori Milken–PCF Young Investigato
Saul Priceman, PhD
City of Hope National Medical Center
Stephen Forman, MD
Targeting Metastatic Prostate Cancer with PSA-Specific Chimeric Antigen Receptor-Engineered T-Cells